[1]
Kario K. Diversity in hypertension and cardiovascular disease around the globe. Curr Hypertens Rev 2021; 17: 1-2.
[2]
Kario K. Perfect 24-hr blood pressure control: up-to-date 2020. Curr Hypertens Rev 2020; 16: 2-10.
[3]
Kario K, Mogi M, Hoshide S. Latest hypertension research to inform clinical practice in Asia Hypertens Res 2022. 45:555-72.
[4]
Zhang W, Zhang S, Deng Y, et al. trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med 2021; 385: 1268-79.
[5]
Zhang WL, Cai J. STEP to blood pressure management of elderly hypertension: evidence from Asia. Hypertens Res 2022; 45: 576-82.
[6]
Blood Pressure Lowering Treatment Trialists’ Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet 2021; 397: 1625-36.
[7]
Kario K. Essential manual of perfect 24-hour blood pressure management from morning to nocturnal hypertension (in press) Pp1-374,. London: Wiley 2022.
[8]
Kario K, Williams B. Nocturnal hypertension and heart failure: Mechanisms, evidence, and new treatments. Hypertension 2021; 78: 564-77.
[9]
Hoshide S, Kanegae H, Kario K. Nighttime home blood pressure as a mediator of N-terminal pro-brain natriuretic peptide in cardiovascular events. Hypertens Res 2021; 44: 1138-46.
[10]
Kario K, Williams B. Angiotensin receptor–neprilysin inhibitors for hypertension -hemodynamic effects and relevance to hypertensive heart disease. Hypertens Res 2022, online
[11]
Kario K, Ito S, Itoh H, Rakugi H, Okuda Y, Yamakawa S. Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes. Hypertens Res 2022; 45: 97-105.
[12]
Katsurada K, Shinohara K, Aoki J, Nanto S, Kario K. Renal denervation: basic and clinical evidence. Hypertens Res 2022; 45: 198-209.
[13]
Kario K, Wang TD. Perspectives of renal denervation from hypertension to heart failure in Asia. Hypertens Res 2022; 45: 193-7.
[14]
Mahfoud F, Kandzari DE, Kario K, et al. Michael Böhm. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs: Results from the randomised, sham-controlled SPYRAL HTN-ON MED trial. Lancet 2022; 399: 1401-10.
[15]
Kario K, Nomura A, Harada N, et al. Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial. Eur Heart J 2021; 42: 4111-22.
[16]
Kario K, Tomitani N, Morimoto T, Kanegae H, Lacy P, Williams B. Relationship between blood pressure repeatedly measured by a wrist-cuff oscillometric wearable blood pressure monitoring device and left ventricular mass index in working hypertensive patients. Hypertens Res 2022; 45: 87-96.
[17]
Accurate nighttime blood pressure monitoring with less sleep disturbance. Tomitani N, Hoshide S, Kario K. Hypertens Res 2021; 44: 1671-3.
[18]
Hoshide S, Yoshihisa A, Tsuchida F, et al. Pulse transit time-estimated blood pressure: a comparison of beat-to-beat and intermittent measurement. Hypertens Res 2022.
[http://dx.doi.org/10.1038/s41440-022-00899-z]
[http://dx.doi.org/10.1038/s41440-022-00899-z]
[19]
Kario K, Harada N, Okura A. State-of-the-art rapid review of the current landscape of digital hypertension. Connect Health 2022. in press
[20]
McFarlane E, Linschoten M, Asselbergs FW, Lacy PS, Jedrzejewski D, Williams B. CAPACITY-COVID Consortium. The impact of pre-existing hypertension and its treatment on outcomes in patients admitted to hospital with COVID-19. Hypertens Res 2022; 45: 834-45.
[21]
Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Hypertens Res 2020; 43: 648-54.
[22]
Kario K, Morisawa Y, Sukonthasarn A, et al. (HOPE Asia) Network. COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network. J Clin Hypertens 2020; 22: 1109-19.
[23]
Shibata S, Arima H, Asayama K, et al. Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertens Res 2020; 43: 1028-46.
[24]
Katsi V, Pavlidis G, Charalambous G, Tousoulis D, Toutouzas K. COVID-19, Angiotensin-converting enzyme 2 and renin-angiotensin system inhibition: implications for practice. Curr Hypertens Rev 2022; 18: 1-8.
[25]
Sadeghi R, Masoudi MR, Patelarou A, Khanjani N. Predictive Factors for the Care and Control of Hypertension Based on the Health Belief Model Among Hypertensive Patients During the COVID-19 Epidemic in Sirjan, Iran. Curr Hypertens Rev 2022; 18: 76-82.
[26]
Walker M, Patel P, Kwon O, Koene RJ, Duprez DA, Kwon Y. Atrial Fibrillation and Hypertension: “Quo Vadis”. Curr Hypertens Rev 2022; 18: 37-51.
Article Metrics
16
1